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Abstract
Pre-eclampsia (PE) is one of the most severe syndromes in human pregnancy, and the underlying mechanisms of PE have yet to be determined.
Pre-eclampsia is characterized by the alteration of the immune system’s activation status, an increase in inflammatory Th1/Th17/APC cells, and
a decrease in Th2/Treg subsets/cytokines. Moreover, inflammatory infiltrates have been detected in the amniotic membranes of pre-eclamptic
placentae, and to this date limited data are available regarding the role of amniotic membrane cells in PE. Interestingly, we and others have pre-
viously shown that human amniotic mesenchymal stromal cells (hAMSC) possess anti-inflammatory properties towards almost all immune
cells described to be altered in PE. In this study we investigated whether the immunomodulatory properties of hAMSC were altered in PE. We
performed a comprehensive study of cell phenotype and investigated the in vitro immunomodulatory properties of hAMSC isolated from pre-
eclamptic pregnancies (PE-hAMSC), comparing them to hAMSC from normal pregnancies (N-hAMSC). We demonstrate that PE-hAMSC inhibit
CD4/CD8 T-cell proliferation, suppress Th1/Th2/Th17 polarization, induce Treg and block dendritic cells and M1 differentiation switching them
to M2 cells. Notably, PE-hAMSC generated a more prominent induction of Treg and higher suppression of interferon-c when compared to N-
hAMSC, and this was associated with higher transforming growth factor-b1 secretion and PD-L2/PD-L1 expression in PE-hAMSC. In conclu-
sion, for the first time we demonstrate that there is no intrinsic impairment of the immunomodulatory features of PE-hAMSC. Our results sug-
gest that amniotic mesenchymal stromal cells do not contribute to the disease, but conversely, could participate in offsetting the inflammatory
environment which characterizes PE.
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Introduction
Pre-eclampsia is one of the main causes of maternal and foetal mor-
bidity and mortality, causing nearly 40% of premature births delivered
before 35 weeks of gestation, and complicating around 2–8% of all
pregnancies worldwide [1, 2]. The physiopathology triggering the dis-
ease is yet unknown, however, it is clear that the development of PE
requires the presence of placenta, as the clinical syndrome does not
develop in the absence of placenta and it disappears soon after birth.
It is also widely accepted that the pathophysiological process of PE
begins with an abnormal trophoblast invasion early in pregnancy,
which produces increased placental oxidative stress contributing to
the development of systemic endothelial dysfunction in the later
phases of the disease [2].
Aberrant/chronic inflammation is considered to be a dominant
component in the pathogenesis of PE. Indeed, in contrast to normal
pregnancy characterized by Th2 type immunological state where Th2
and Treg cell responses and cytokine profiles predominate, in PE
there is a predominance of Th1-type immunity and pro-inflammatory
cytokines [3–5]. In addition to the imbalance of Th1 and Th2 cells,
increases of Th17 and reduction in Treg cells have also been found in
maternal blood [6–8] and placenta [9]. Although some authors did
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not find different numbers of Treg cells between pre-eclamptic
patients and women with uncomplicated pregnancies [10, 11], others
have shown that the numbers of circulating Treg cells in PE are
decreased compared to those in healthy pregnant women [12, 13].
Moreover, the abnormal activation status of antigen presenting cells
(APC) [specifically monocytes, macrophages and dendritic cells (DC)]
was found in pre-eclamptic placentae [14, 15]. Indeed, in normal
pregnancy, most of the macrophages are anti-inflammatory/im-
munomodulatory M2 macrophages, while in PE, there appears to be
increased numbers of inflammatory M1 macrophages [16].
The mechanisms underlying this aberrant inflammatory profile
need to be elucidated. However, it is plausible that it arises from the
lack of or altered immune regulation/modulation. Indeed, foetal–
maternal tolerance, a fundamental process for a successful pregnancy,
is thought to be altered in PE [17]. Interestingly, increasing evidence
supports the idea that mesenchymal stem/stromal cells (MSC),
derived from both maternal and foetal compartments, strongly con-
tribute to foetal–maternal tolerance, mainly because of their broad
immune regulatory properties [18–23]. Within foetal MSC, the
immune regulatory properties of MSC from human amniotic mem-
brane (hAMSC) are obtaining growing interest [24, 25]. We and others
have demonstrated that hAMSC are able to modulate lymphocyte pro-
liferation when cultured either in contact or non-contact (transwell
system) with lymphocytes, and even when the conditioned medium
(CM) derived from the culture of unstimulated hAMSC was used
instead of the cells [26–30]. The use of CM and the transwell system
demonstrated that hAMSC could act on activated lymphocytes through
constitutively produced, inhibitory secreted factor(s), without the need
for cell-to-cell contact or activating stimuli. We recently demonstrated
that hAMSC reduce the expression of the markers associated with the
Th1 and Th17 populations, and significantly induce the regulatory
T-cell compartment [30]. Furthermore, others have shown that not
only T lymphocytes but also the cytotoxicity of natural killer cells (NK)
were affected by amniotic membrane-derived cells [31]. Moreover, we
and others have shown that hAMSC also act on the monocytes sup-
pressing their differentiation towards [32–34]. Interestingly, hAMSC
do not simply block the differentiation of monocytes, but skew differ-
entiation into anti-inflammatory M2 macrophage-like cells [33].
Overall, these results suggest that hAMSC could regulate different
immune cell types which are described to be dysregulated in PE.
Moreover, lesions of amniotic basement membrane associated with
inflammatory infiltrate, as well as inflammatory reaction of the
amnion, have been found in PE [35, 36]. Whether or not the
immunomodulatory properties of hAMSC are altered in or contribute
to the development of PE remains to be understood.
The aim of this study was to understand if hAMSC isolated from
PE (PE-hAMSC) pregnancies presented altered immunological fea-
tures. To this end, we compared the immunomodulatory properties of
PE-hAMSC with those from normal/uncomplicated pregnancies (N-
hAMSC), both from the third trimester. We performed a comprehen-
sive study of cell surface phenotype, ability to suppress T-cell prolif-
eration and to trigger their polarization towards CD4 Th1, Th2, Th17,
Treg cells and CD8 cytotoxic T cells. Finally, we also compared their
ability to affect monocyte differentiation towards DC, M1 and M2
macrophage-like cells.
Materials and methods
Ethic statement
Healthy and pre-eclamptic human placentae were collected after obtain-
ing informed written consent according to the guidelines set by the Eth-
ical Committee of the Catholic Hospital (CEIOC) (Document ‘Parere 16/
2012’) and Institutional Ethical Review Board of O.I.R.M. S.Anna Hospi-
tal, Turin and ‘Ordine Mauriziano di Torino’ (n.209; protocol 39226/
C.27.1 04/08/09), respectively.
Isolation and culturing of hAMSC
Human placentae from both normal and pre-eclamptic pregnancies were
collected and processed immediately. Pre-eclamptic placentae were
selected according to previously described criteria [37]. Human amniotic
mesenchymal stromal cells were isolated as previously described [29].
Both freshly isolated (p0) PE-hAMSC and N-hAMSC were sub-
cultured until passages 4 (p4) by plating at a density of 104/cm2 in Chang
medium C (Irvine Scientific, Santa Ana, CA, USA) supplemented with
2 mM L glutamine. The study was performed with PE-hAMSC at gesta-
tional age of 31.5  2.6 (n = 6) and, given the difficulty in obtaining
healthy/normal placentae from preterm pregnancies, we used N-hAMSC
from term placentae (n = 6, gestational age = 38.8  0.44) (Table 1).
hAMSC phenotype analysis
Surface phenotype of N- and PE-hAMSC at p4 were investigated by flow
cytometry following standard protocols as previously reported [33].
Cells were acquired with a FACSCalibur (BD Biosciences, San Jose, CA,
USA) and analysed with FCS express v4.07 (DeNovo Software, Los
Angeles, CA, USA). Dead cells were gated out by propidium iodide
staining (0.1 lg/ml; Sigma-Aldrich, St Louis, MO, USA). Antibodies and
suppliers used are described in Table 2.
Isolation of peripheral blood mononuclear cells,
T cells, and monocytes
Peripheral blood was collected from healthy adult donors. Human periph-
eral blood mononuclear cells (PBMCs) were obtained by density gradient
centrifugation (Histopaque; Sigma-Aldrich) of buffy coats. PBMC were
c-irradiated (30 Gy) prior to use as allogeneic stimulators. T lymphocytes
and monocytes were purified from PBMC by using Pan T cell Isolation Kit
II and anti-CD14-coated microbeads, respectively, according to the manu-
facturer’s instructions (both from Miltenyi Biotec, Bergisch Gladbach,
Germany).
Mixed lymphocyte culture
Co-cultures of T cells with N- and PE-hAMSC were established in direct
cell-to-cell contact. Around 105 hAMSC were seeded in 96-well plates
(Nunc, Roskilde, Denmark) in 150 ll of UltraCulture medium (Lonza,
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Basel, CH, Switzerland) and irradiated (30 Gy) to block proliferation.
The day after, mixed lymphocyte cultures (MLC) were obtained by cul-
turing 105 T lymphocytes and 105 c-irradiated allogeneic PBMC in
100 ll of UltraCulture medium (Lonza), in the absence (controls) or
presence of hAMSC. T-cell proliferation was assessed by 5-ethynyl-
20deoxyuridine (EdU) incorporation as previously described [38]. Briefly,
10 lM EdU (Life Technologies, Carlsbad, CA, USA) was added on day 5
and incubated for 16–18 hrs. Incorporated EdU was detected by the
Cu-catalysed alkyne-azide cycloaddition (CuAAC or ‘click’) reaction of
the ethynyl group with 2.5 lM 3-azido-7-hydroxycoumarin (Jena Bio-
sciences, Jena, Germany), in buffer solution (100 mM Tris-HCl pH 8.0,
10 mM L-ascorbic acid, 2 mM CuSO4) at RT for 30 min. The samples
were acquired with a FACSAria (BD Biosciences) and analysed with FCS
express v4.07 (DeNovo Software).
Analysis of different T-cell subsets
The phenotypes of different T-cell subsets derived from MLC experiments
were assessed after 6 days of co-culturing by FACS analysis using a set
of cell surface markers and intracellular cytokines to characterize CD4+ T
helper (Th) cells Th1 [39, 40], Th2 [39, 40], Th17 [39, 40], Treg [41] and
CD8+ cytotoxic T lymphocytes (CTL) [42], as reported in Table 2. Before
fixation, samples were stained with Zombie NIR Live/Dead Cell Kit to
remove dead cells from the analysis (eBiosciences, San Diego, CA, USA).
Cells were then fixed, stained for surface antigens, permeabilized and
stained for intracellular antigens as reported in [30]. In parallel, cells from
MLC experiments were also evaluated for T-cell intracellular cytokine pro-
duction. Therefore, cells were stimulated for 5 hrs at 37°C with phorbol-
12-myristate-13-acetate (50 ng/ml), calcium-ionomycin (CaI, 1 lg/ml)
and Brefeldin A (10 lg/ml) (all from Sigma-Aldrich), and viable cells were
analysed on a flow cytometer.
Detection of secreted cytokines
The supernatant from MLC experiments was collected 2 and 6 days
after culturing. Quantification of secreted interferon (IFN)-c, interleukin
(IL)-1-b, IL-2, IL-5, IL-9, IL-10, IL-13, IL-22, sIL-2R, tumour necrosis
factor (TNF)-a and transforming growth factor (TGF)-b was evalua-
ted by using a multiple cytometric bead array system FlowCytoMix
(eBiosciences), according to the manufacturer’s instructions. Samples
were acquired with a FACSAria (BD Biosciences) and analysed with
FlowCytomix Pro software (eBiosciences).
Table 1 Clinical features of the study population
Healthy (n = 6) Pre-eclampsia (n = 6) P-value
Nulliparae (%) 33 50 n.s.
Gestational age at delivery (weeks, median – range) 38.5 (38–39) 31.6 (28–35) <0.001
Maternal age at delivery (years, median – range) 31 (25–38) 35.5 (33–46) n.s.
Caucasian ethnicity (%) 100 100 n.s.
Smokers (%) 0 0 n.s.
Alcohol (%) 0 0 n.s.
Previous prenatal admission (%) 16.7 50
Systolic Blood pressure (mmHg, median – range) 112.5 (90–140) 164 (155–170) <0.001
Diastolic blood pressure (mmHg, median – range) 70 (60–80) 99.5 (90–104) <0.001
Proteinuria (g/24 hr, median – range) Absent 6.4 (0.86–15) <0.05
A/REDF (%) 0 17 n.s.
Pathological uterine Doppler (%) 0 83 <0.05
Labour (%) 50 17 n.s.
Caesarean section (%) 66.7 83 n.s.
Birth weight (g, median – range) 2922.5 (2375–3750) 1307.5 (880–2500) <0.001
Placental weight (g median – range) 590 (450–600) 225.5 (150–395) <0.001
Foetal sex
Male (%) 33 33 n.s.
Female (%) 67 67 n.s.
n.s.: not significant.
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Generation of monocyte-derived DC, M1 and M2
macrophage-like cells
Dendritic cells were obtained by culturing 1 9 106 CD14+ monocytes
as previously described [33]. To obtain the herein termed M1 and M2
macrophage-like cells, 0.5 9 106 CD14+ monocytes were cultured for
4 days with 5 ng/ml human recombinant Granulocyte macrophage-colony
stimulating (GM-CSF) (Miltenyi Biotec) or 20 ng/ml M-CSF (Miltenyi
Biotec) respectively. M1 were then treated with 20 ng/ml IFN-c (BD Bio-
sciences) and 100 ng/ml Lipopolysaccharide (LPS) (Sigma-Aldrich),
whereas M2 with 20 ng/ml IL-4 (by Dr. Schweighoffer, Novartis,
Vienna, Austria) and 100 ng/ml LPS (Sigma-Aldrich), for 2 days. All cul-
tures were performed in 24-well plates (Corning, Corning, NY, USA) at
Table 2 Antibodies used for flow cytometry analysis
hAMSC phenotype
Mesenchymal
stromal cell
markers
CD10 (Neprilysin) FITC, CD13 (Aminopeptidase N) PE, CD26 (Dipeptidyl peptidase 4) FITC, CD44 (CD44 antigen)
FITC, CD73 (50-NT) PE, CD90 (Thy-1) FITC, CD105 (Endoglin) FITC, CD106 (VCAM-1) PE, CD109 (CD109 antigen)
PE, CD140b (PDGFR-beta) PE, CD146 (MUC18) PE, CD166 (ALCAM) PE, CD200 (OX20) PE, CD271 (NFGR) APC
Co-stimulatory
molecules
B7-H4 APC, CD59 (CD59 glycoprotein) FITC, CD70 (CD70 antigen) FITC, CD85a (LIR-3) Alexa Fluor 488,
CD152 (CTLA-4) APC, CD154 (CD40L) FITC, CD244 (2B4) FITC, CD252 (OX40-L) PE, CD272 (BTLA) PE, CD273
(PD-L2) APC, CD274 (PD-L1) PE, CD275 (ICOS ligand) PE, CD282 (Toll-like receptor 2) FITC, CD284 (Toll-like
receptor 4) PE, CD357 (AITR/GITR) APC*
Haematopoietic
markers
CD33 (Siglec-3) FITC, CD34 (Haematopoietic progenitor cell antigen CD34) FITC, CD45 (L-CA) APC
Human leucocyte
antigens
class I and II
HLA-ABC FITC, HLA-DM PE, HLA-DQ FITC, HLA-DR APC, HLA-G FITC†
Cytokine receptors CD114 (G-CSFR) PE, CD116 (GM-CSFR) PE, CD119 (IFN-gamma receptor 1) PE, CD120b (TNF-RII) PE, CD124
(IL-4Ra) PE
Integrins and
adhesion molecules
CD49a (Integrin alpha-1) Alexa Fluor 488, CD49b (Integrin alpha-2) FITC, CD49c (Integrin alpha-3) PE, CD49d
(Integrin alpha-4) PE
Others CD31 (PECAM-1) FITC, CD39 (NTPDase 1) PE-Cy7*, CD52 (CAMPATH-1) FITC, CD117 (c-kit) APC, SSEA-4 PE
T-cell subset analysis
Th1 CD4 BV421/BV510/BB515, CD45RA FITC/PerCP-CyTM5.5, CD183 (CXCR3) PE-CyTM7, IFN-c PE-CF594, TNFa PE-Cy7
Th2 CD4 BV421/BV510/BB515, CD45RA FITC/PerCP-CyTM5.5, CD294 (Prostaglandin D2 receptor 2) PE-CF594,
IL-4 BV421, IL-13 PE
Th17 CD4 BV421/BV510/BB515, CD45RA FITC/PerCP-CyTM5.5, CD161 (NKR-P1A) Alexa Fluor 647, IL-17A PE, IL-17F
Alexa Fluor 647
Treg CD4 BV421/BV510/BB515, CD45RA FITC/PerCP-CyTM5.5,
CD25 (IL-2-RA) PerCP-CyTM5.5, FoxP3 PE-CF594, TGF-b1 BV421
CTL CD8 BV510/Alexa Fluor 647, CD45RA FITC/PerCP-CyTM5.5, Granzyme B PE-CF594, TNFa PE-Cy7
Monocytes analysis
DC/macrophage
markers
CD1a (T-cell surface glycoprotein CD1a) FITC, CD14 (Monocyte differentiation antigen CD14) PE-Cy7, CD83
(CD83 antigen) PE, CD163 (Scavenger receptor cysteine-rich type 1 protein M130) BV421, CD197
(C-C chemokine receptor type 7) Alexa Fluor 647, CD209 (DC-SIGN) PerCP-Cy5.5
Co-stimulatory
molecules
CD40 (Tumour necrosis factor receptor superfamily member 5) FITC, CD80 (T-lymphocyte activation antigen
CD80) FITC, CD273 (PD-L2) APC, CD274 (PD-L1) BV421
*eBiosciences, San Diego, CA, USA.
†Bio-Rad AbD Serotec, Raleigh, NC, USA.
All antibodies were purchased from BD Biosciences, unless otherwise specified.
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37°C in 1 ml of Roswell Park Memorial Institute (RPMI) complete med-
ium.
Exposure of monocytes to hAMSC
Monocytes were differentiated towards DC, M1- and M2 macrophage-like
cells in the absence (controls) or presence of normal and PE hAMSC,
either in direct cell-to-cell contact or with physical separation using tran-
swell chambers. hAMSC were seeded in 24-well plates in 0.5 ml (for con-
tact experiments) or in 0.3 ml of RPMI complete medium in the upper
compartment of a transwell (0.4 lm pore, polycarbonate membrane;
Corning) and then irradiated (30 Gy). The day after, monocytes in RPMI
complete medium were added into the same well (contact experiments)
or into the lower compartment of 24-well plates (transwell experiments)
at a monocyte: hAMSC ratio of 1:0.05 (contact experiments) or 1:0.4
(transwell experiments). Dendritic cells and macrophage differentiation
was carried out with appropriate stimuli, as described above.
Monocytes phenotype analysis
Monocytes were differentiated towards DC, M1- and M2 macrophage-
like cells in the absence or presence of hAMSC (as described above).
After culturing, the monocytes were collected by gently scraping cells
from the wells. Surface phenotype was investigated by flow cytometry
as previously reported [33], using cell markers described to be
expressed by DC [43, 44], M1- [45] and M2 [45, 46] macrophages.
Cells were acquired with a FACSAria (BD Biosciences) and analysed
with the FCS express v4.07 (DeNovo Software). Antibodies and suppli-
ers used in this study are described in Table 2.
Statistical analysis
Unless otherwise indicated, the results were obtained from six indepen-
dent experiments, and are represented as median and interquartile
range. Statistical analysis was performed by both parametric and non-
parametric approaches. Comparison between two groups (results shown
in Table 1 and Fig. 1) was performed by unpaired t-test and Mann–
Whitney test. For all the other results, statistical analysis was performed
by one-way ANOVA followed by the Bonferroni post hoc test, and
Kruskal–Wallis ANOVA by ranks. Analyses were performed with GraphPad
Prism 6 software (GraphPad Software, San Diego, CA, USA). A P-value
lower than 0.05 was considered statistically significant.
Results
Phenotype analysis of N-hAMSC and PE-hAMSC
N-hAMSC and PE-hAMSC were cultured up to passage 4 (P4). Both
N-hAMSC and PE-hAMSC formed a monolayer of fibroblast-like cells
with the typical mesenchymal stromal morphology without visible
morphological differences (data not shown).
We analysed the phenotype of cells at P4 for the expression of
selected markers (Fig. 1). These include those described to be
expressed by MSC (Fig. 1A), co-stimulatory molecules (Fig. 1B),
haematopoietic markers (Fig. 1C), human leucocyte antigens (HLA)
class I and class II (Fig. 1D), cytokine receptors (Fig. 1E), integrins
and adhesion molecules (Fig. 1F), and others (Fig. 1G).
Flow cytometry analysis revealed that the surface marker profile of
PE-hAMSC was similar to that of N-hAMSC. Specifically, both PE-hAMSC
and N-hAMSC expressed all the MSC markers examined, with the excep-
tion of CD106, CD109 and CD271 (Fig. 1A). Furthermore, they
expressed different integrins and adhesion molecules (Fig. 1F). More-
over, they expressed HLA-ABC (HLA class I), but lacked HLA-G (non-
classical HLA class I) and HLA-DM, -DQ, -DR (HLA class II) (Fig. 1D).
They were negative (or weakly positive) for haematopoietic markers
(Fig. 1C), cytokine receptors (Fig. 1E), and CD31, the ectonucleotidase
CD39, and CD52 (Fig. 1G). Among the co-stimulatory molecules tested,
they expressed CD59, CD85a, CD252, CD272, CD273, CD274 and
CD284, and were negative for the other molecules investigated (Fig. 1B).
Even though PE-hAMSC and N-hAMSC had similar profiles, sev-
eral quantitative differences were found. The expression of CD146
and of co-stimulatory molecule CD273 (PD-L2) was significantly
higher in PE-hAMSC than in N-hAMSC (Fig. 1A and B). Similarly, the
expression of CD274 (PD-L1) was higher in PE-hAMSC when com-
pared to N-hAMSC, although the difference did not reach statistical
significance (Fig. 1B).
The effects of N-hAMSC and PE-hAMSC on T-cell
proliferation and polarization
We have previously demonstrated that hAMSC, either freshly isolated
(passage 0) or after cell expansion, are able to modulate lymphocyte
proliferation [27]. Herein, we compared the effects of hAMSC derived
from normal and pre-eclamptic placentae on the proliferation of CD4+
and CD8+ lymphocytes. As shown in Figure 2, both N- and PE-hAMSC
suppressed the proliferation of both CD4+ Th cells and CD8+ CTL.
To assess the effects of N-hAMSCs and PE-hAMSCs on the polar-
ization of T cells, we evaluated the phenotype of CD4+ (Th and Treg)
and CD8+ (cytotoxic) cells using different surface and intracellular
markers. As shown in Figure 3 (Th1 panel), both N-hAMSC and
PE-hAMSC significantly reduced the percentage of markers associated
to Th1 cells, such as CD183+ (CXCR3), IFN-c+ and TNF-a+. Further-
more, co-culturing with both N-hAMSC and PE-hAMSC significantly
reduced the percentage of cells positive for markers associated with
the Th2 population, such as CD294 (CRTH2) and IL-4, however, no
changes were observed in the percentage of cells expressing IL-13
(Fig. 3, Th2 panel). Regarding Th17 population, both N-hAMSC and
PE-hAMSC reduced the percentage of cells positive for CD161 (KLRB1)
and IL-17A, whereas no significant changes were observed in the per-
centage of CD4+ expressing IL-17F (Fig. 3, Th17 panel). Finally, we
observed that both N-hAMSC and PE-hAMSC significantly modulated
the T regulatory (Treg) compartment (Fig. 3, Treg panel) identified as
CD4+ CD45RA-CD25high and CD4+ CD45RA-CD25highFoxP3+ cells.
Both N-hAMSC and PE-hAMSC significantly increased CD25high and
CD25highFoxP3+ cells, and interestingly, PE-hAMSC to a greater extent
than N-hAMSC. Neither N-hAMSC nor PE-hAMSC were able to signifi-
cantly alter the percentage of TGF-b-expressing CD4+ cells.
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To investigate the effects of N-hAMSC and PE-hAMSC on CD8
CTL, we evaluated intracellular GranzymeB and TNF-a expressed on
CD8+ cells after co-culturing with either normal or pre-eclamptic cells.
We observed that both N-hAMSC and PE-hAMSC intensively modu-
late CTLs by reducing GranzymeB and TNF-a-expressing cells (Fig. 3,
CTL panel). Taken together, we show that both N-hAMSC and
PE-hAMSC are able to inhibit the proliferation of alloreactive T lym-
phocytes and down-regulate the Th pathway in a similar manner. Both
normal and pre-eclamptic cells can significantly enhance the Treg
compartment, but pre-eclamptic cells to a greater extent.
The effects of N-hAMSC and PE-hAMSC on
secreted cytokines
To provide further insight into which T-cell subsets were altered by
N-hAMSC and PE-hAMSC, we studied T-cell cytokine profiles 2 and
6 days after co-culturing with normal or pre-eclamptic cells. The
panel of cytokines analysed for the different T-cell subsets are as fol-
lows: IFN-c, TNF-a, IL-1b, IL-2, IL-5, IL-9, IL-10, IL-13, IL-22, TGF-
b1, sIL-2R.
N-hAMSC and PE-hAMSC significantly inhibited the secretion of
pro-inflammatory Th1-cytokines TNF-a and IFN-c, 2 and 6 days after
co-culturing (Fig. 4). Six days after co-culturing, the inhibition of IFN-
c was stronger with PE-hAMSC (P < 0.05) compared to that seen
with N-hAMSC. Interestingly, IL-1b secretion increased over time in
the presence of N-hAMSC and PE-hAMSC, even if PE-hAMSC
released more IL-1b per se (Fig. 4). The presence of N-hAMSC or PE-
hAMSC induced the secretion of IL-2 at day 2 of co-culturing, and this
induction decreased at day 6, but remained higher in the presence of
PE-hAMSC. The secretion of IL-5, a Th2-related cytokine, was
markedly reduced by the presence of N-hAMSC and PE-hAMSC, but
PE-hAMSC induced a stronger inhibition of IL-5 at day 6 (P < 0.05).
Conversely, 6 days after co-culturing with either N-hAMSC or
PE-hAMSC, we observed an increase in the secretion of IL-13
(Fig. 4). The release of Th17- related cytokine IL-22 and Th9-related
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Fig. 1 Immunophenotype of N-hAMSC and
PE-hAMSC. N-hAMSC (n = 4) (h) and
PE-hAMSC (n = 5) ( ) at p4 were anal-
ysed by flow cytometry for markers
described to be expressed by MSC (A),
co-stimulatory molecules (B), haematopoi-
etic markers (C), human leucocyte anti-
gens (HLA) class I and class II (D),
cytokine receptors (E), integrins and adhe-
sion molecules (F), and others (G).
-P = 0.07; *P < 0.05; **P < 0.01.
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cytokine IL-9 were inhibited by both N-hAMSC and PE-hAMSC, and
the reduction observed in the presence of PE-hAMSC reached signifi-
cance after 6 days of co-culturing (P < 0.05, Fig. 4). The presence of
N-hAMSC or PE-hAMSC induced the secretion of IL-10 starting
2 days after co-culturing, and this induction was greater in the pres-
ence of PE-hAMSC (P < 0.05), but completely lost after 6 days
(Fig. 4). TGF-b1 was significantly higher in the presence of N-hAMSC
or PE-hAMSC, but this effect is likely because of the amount of TGF-
b1 secreted by hAMSC (both N- and PE-) per se. Of note, both 2 and
6 days after co-culturing PE-hAMSC released more TGF-b1 compared
to N-hAMSC. Finally, sIL-2R secretion significantly increased in the
presence of N-hAMSC or PE-hAMSC after 6 days, and PE-hAMSC
induced a stronger release of sIL-2R (Fig. 4).
Impact of N-hAMSC and PE-hAMSC on the
differentiation of monocytes towards DC, M1 and
M2 macrophage-like cells
Because of the important role of the activation status of antigen pre-
senting cells in the pathophysiology of PE [16], we compared the
effects of N-hAMSC or PE-hAMSC on the differentiation of peripheral
blood CD14+ monocytes towards DC, M1-, and M2 macrophage-like
cells. This was performed in the absence or presence of N-hAMSC or
PE-hAMSC, either in direct contact with monocytes or with physical
separation using a transwell system. After differentiation, cells were
analysed using a panel of surface markers and co-stimulatory mole-
cules to discriminate between DC, M1, and M2-derived macrophages.
As shown in Figures 5 and 6, DC were characterized by the expression
of CD1a, CD209 (DC-SIGN), activation marker CD197 (chemokine
receptor CCR7) and CD83, and co-stimulatory molecules CD40, CD80,
CD274 (PD-L1) and CD273 (PD-L2), whereas they lacked CD14 and
CD163. Similar to DC, M1 macrophage-like cells were characterized by
a higher expression of activation and co-stimulatory molecules such
as CD197, CD83, CD40, CD80, CD274 (PD-L1) and CD273 (PD-L2)
(Figs 5 and 6) and low/absent expression of CD14, and CD163 (Figs 5
and 6). However, compared to DC, M1 macrophage-like cells were
negative for CD209 and showed an intermediate expression of CD1a
(Fig. 5). On the other hand, M2 macrophage-like cells expressed
CD14, CD163 and CD209 (Fig. 5). When compared to DC and M1, M2
macrophage-like cells expressed reduced levels of CD40, CD80
(Fig. 6) and were negative for CD1a, CD83 and CD197 (Fig. 5).
When monocytes were differentiated towards DC in the presence
of hAMSC, we observed that both N-hAMSC and PE-hAMSC induced
the complete inhibition of DC differentiation. Indeed, these monocytes
failed to express CD1a, but highly expressed CD14 and CD163 (Fig. 5).
Moreover, the activation of the co-stimulatory molecules CD197,
CD83, CD40, CD80 and CD274 (PD-L1) were highly suppressed
(Figs 5 and 6). These effects were observed in both contact (Figs 5
and 6) and transwell settings (data not shown), without significant dif-
ferences. Similarly, when monocytes were differentiated under M1 cul-
ture conditions in the presence of either N-hAMSC or PE-hAMSC, we
observed the same inhibitory effect without significant differences.
Specifically, they highly expressed CD14, CD163 and had increased
CD209 expression (Fig. 5). Furthermore, when differentiated in the
presence of N-hAMSC and PE-hAMSC, we observed a reduced expres-
sion of CD1a, CD197, CD83, CD80 and CD273 (PD-L2) (Figs 5 and 6),
whereas the expression of CD40 and CD274 (PD-L1) did not change
compared to control M1 macrophage-like cells (Fig. 6). Overall, the
expression of CD14, CD163 and CD209 combined with the absence/re-
duced expression of CD1a, CD197, CD83 and CD80 indicate that the
differentiation of monocytes towards DC and M1 macrophage-like cells
was not only inhibited, but switched towards M2-like cells.
Instead, when monocytes were treated under M2 conditions in
the presence of either N-hAMSC or PE-hAMSC, their phenotype was
almost unchanged. They expressed the same markers of control M2
macrophage-like cells, but CD14 and CD209 to a higher extent
(Fig. 5), and CD83, CD80 and CD274 to a lower extent (Figs 5 and 6).
In the non-contact setting (transwell system), the expression of CD40
was also reduced (data not shown).
Discussion
In this study, we investigated the in vitro immunomodulatory proper-
ties of hAMSC isolated from pre-eclamptic pregnancies (PE-hAMSC),
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and compared them to hAMSC from the placentae of normal, uncom-
plicated pregnancies (N-hAMSC). To our knowledge, this is the first
study demonstrating that PE-hAMSC maintain the same immunomod-
ulatory features as N-hAMSC. Notably, PE-hAMSC generated a more
prominent induction of Tregs, when compared to N-hAMSC, and sim-
ilar to N-hAMSC, were able to block monocyte differentiation towards
DC and M1.
Pre-eclampsia is one of the most severe syndromes in human
pregnancy, leading to maternal and neonatal morbidity and mortal-
ity, but the physiopathology that triggers the disease is still not
understood. During PE, alteration of the activation status of the
immune system occurs, and specifically, PE is characterized by the
increase in inflammatory Th1/Th17/APC and decrease in Th2/Treg
cytokines/subsets. These alterations have been reported in systemic
(maternal blood) levels [6–8], and locally in the maternal–foetal
interface (decidua and trophoblast) [9, 15]. However, inflammatory
infiltrates were also found in other foetal compartments of pre-
eclamptic placentae, such as the chorionic villi and amniotic mem-
brane [35, 36].
Nevertheless, in PE, limited data are available regarding foetal tis-
sues, specifically on amniotic membranes. Interestingly, within the
amniotic membrane, hAMSC have been described to possess broad
anti-proliferative and anti-inflammatory properties towards almost all
immune cells whose phenotype, activation status or distribution were
described to be altered in PE. Whether alterations of hAMSC’s
immunomodulatory properties may be present in PE remain
unknown, and comparing the immunomodulatory properties of
hAMSC from normal and pre-eclamptic pregnancies might provide
insight into this disorder.
For the most part, and in line with other reports [47, 48], our
studies show that the phenotype of PE-hAMSC is similar to that of N-
hAMSC. Interestingly, we observed a significant increase in CD146
(MUC18) expression which could be related to the higher TGF-b1 pro-
duction in PE-hAMSC when compared to N-hAMSC. Accordingly, pre-
vious reports have shown that TGF-b1 increases the expression of
CD146 on MSC [49]. Furthermore, we also observed a higher expres-
sion of CD273 (PD-L2) and CD274 (PD-L1) in PE-hAMSC. This could
be related to the inflammatory environment from which PE-hAMSC
derive, in line with previous reports showing that IFN-c inflammatory
priming increases PD-L2 and PD-L1 expression in hAMSC [50].
However, we cannot exclude that these phenotype differences
could be because of the different gestational age of PE-hAMSC
(31.6  2.6 weeks) compared to N-hAMSC (38.8  0.5 weeks).
In fact, others have shown that gestational age can impact the
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phenotype of epithelial cells from the amniotic membrane of ovine
placentae [51].
Next, we investigated the immunomodulatory features hAMSC
and demonstrate that PE- hAMSC retain similar, and even in some
cases enhanced, immunomodulatory properties than N-hAMSC.
Indeed, both PE-hAMSC and N-hAMSC suppress both CD4 and CD8
T-cell proliferation, at passage 0 (data not shown) as well as at pas-
sage 4. They also were able to reduce the expression of GranzymeB
and TNF-a in CD8 cytotoxic T cells. Within the CD4 population,
PE-hAMSC reduced the expression of markers associated to Th1, Th2
and Th17 populations, as well as their specific subset-related cytoki-
nes, such as TNF-a, IFN-c, IL-1b (Th1-related), IL-5 (Th2), IL-9 (Th9)
and IL-22 (Th17), and, remarkably, the suppression of IFN-c and IL-5
was higher in the presence of PE-hAMSC than N-hAMSC. Of note,
PE-hAMSC were more capable of increasing the percentage of Tregs.
In line with these results, we found more IL-2 and IL-10 secretion in
T cells co-cultured with PE-hAMSC than those co-cultured with
N-hAMSC. Both cytokines have been described to be important for
Treg survival and suppressive functions [52, 53]. Interestingly, we
found more secretion of TGF-b1 and higher expression of PD-L1 and
PD-L2 in PE-hAMSC than N-hAMSC. The increased level of TGF-b1
has been also previously reported in maternal serum [54, 55] and pla-
cental tissues [37, 56, 57] from pre-eclamptic patients. Moreover,
TGF-b1, PD-L1 and PD-L2 have been described to inhibit T-cell recep-
tor signalling, T-cell proliferation, production of cytokines such as
IFN-c and TNF-a, and to regulate the generation of peripheral Tregs
and the suppression of effector T cells [58, 59]. Thus, the higher
secretion of TGF-b1 and higher expression of PD-L2 and PD-L1 found
in PE-hAMSC could explain the higher suppression of IFN-c and
higher induction of Treg observed with PE-hAMSC. Finally, we also
show that PE-hAMSC not only act on T cells but are also able to inhi-
bit the differentiation of monocytes towards both DC and inflamma-
tory M1 macrophages, switching them into an anti-inflammatory/
regulatory M2 profile, a characteristic common to N-hAMSC [33].
In this study, we have demonstrated that PE-hAMSC are able to
inhibit both CD4 and CD8 T-cell proliferation, and to suppress the dif-
ferentiation of monocytes towards DC and M1 macrophages, as
described for N-hAMSC [21]. Previously, others have shown similar
cytokine secretion profiles between hAMSC from PE and normal preg-
nancies [47]. Although these results have to be confirmed by a larger
sample size, overall, these data corroborate the hypothesis that there
is no intrinsic impairment of the immunomodulatory features of
hAMSC in PE. Our observations that PE-hAMSC suppress Th1/Th2/
Th17 polarization, and induce regulatory T and M2 cells, could possi-
bly suggest their contribution to creating a microenvironment useful
for a successful/healthy pregnancy. Interestingly, PE-hAMSC have
more pronounced capabilities of suppressing Th1 (IFN-c production)
and inducing Treg formation when compared to N-hAMSC. These
findings suggest that PE-hAMSC do not possess an intrinsic defect
nor do they participate to the disease mechanism, but conversely, it
seems that PE-hAMSC could efficiently counteract the inflammatory
environment that characterizes PE and, ultimately, help foetal sur-
vival.
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